Quarterly ResultMay 15, 2026, 05:07 PM
CEL SCI Q2 Net Loss $(5.47)M; Going Concern Doubt
AI Summary
CEL SCI Corporation reported a net loss of $(5,465,751) for the three months ended March 31, 2026, and $(10,935,197) for the six months, showing a reduction in losses compared to the prior year. However, the company's cash and cash equivalents significantly decreased to $1.89 million from $10.95 million over the past six months, leading to substantial doubt about its ability to continue as a going concern. The company plans to raise additional capital through partnerships, debt, and/or equity financings to fund its operations and bring its lead investigational therapy, Multikine, to market.
Key Highlights
- Net loss for the six months ended March 31, 2026, was $(10,935,197), down from $(13,645,451) in 2025.
- Net loss for the three months ended March 31, 2026, was $(5,465,751), down from $(6,572,389) in 2025.
- Cash and cash equivalents decreased to $1,890,732 at March 31, 2026, from $10,953,460 at September 30, 2025.
- Total assets declined to $17,707,274 at March 31, 2026, from $28,155,748 at September 30, 2025.
- Total stockholders' equity decreased to $6,874,674 at March 31, 2026, from $15,957,085 at September 30, 2025.
- Research and development expenses for the six months decreased to $7,444,145 from $8,444,328.
- General & administrative expenses for the six months decreased to $3,250,670 from $4,843,193.
- The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and future liquidity needs.
Price Impact
More from CVM